Host genetics shape the gut microbiota, and gut dysbiosis increases the risk of acute graft-versus-host disease (aGVHD). Paneth cells and microbiota have interactions that contribute to immune regulation. a-defensin-5 (HD5) and regenerating islet-derived protein 3 alpha (Reg3A) are the most abundant Paneth cell antimicrobial peptides (AMPs). We hypothesized that single nucleotide polymorphisms (SNPs) in the genes for HD5 (DEFA5) and Reg3A (REG3A) predict aGVHD risk. We analysed pre-transplant recipient peripheral blood mononuclear cell samples from randomized Blood and Marrow Transplant Clinical Trials Network (BMT CTN) studies 0201 (94 patients with bone marrow and 93 with peripheral blood grafts) and 0901 (86 patients with myeloablative and 77 with reduced-intensity conditioning; all using peripheral blood grafts). In multivariable analysis (with a SNP 9 graft source interaction term in CTN-0201 and a SNP 9 conditioning intensity term in CTN-0901), DEFA5 rs4415345 and rs4610776 were associated with altered incidence of aGVHD grade II-IV [rs4415345 G vs. C: hazard ratio (HR) 0Á58, 95% confidence interval (95% CI) 0Á37-0Á92, P = 0Á02; rs4610776 T vs. A: HR 1Á53, 95% CI 1Á01-2Á32, P = 0Á05] in CTN-0201, but not CTN-0901, suggesting a stronger effect in bone marrow allografts. REG3A SNP was not associated with aGVHD. Host genetics may influence aGVHD risk by modulating Paneth cell function.
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Host genetics shape the gut microbiota, and gut dysbiosis increases the risk of acute graft-versus-host disease (aGVHD). Paneth cells and microbiota have interactions that contribute to immune regulation. a-defensin-5 (HD5) and regenerating islet-derived protein 3 alpha (Reg3A) are the most abundant Paneth cell antimicrobial peptides (AMPs). We hypothesized that single nucleotide polymorphisms (SNPs) in the genes for HD5 (DEFA5) and Reg3A (REG3A) predict aGVHD risk. We analysed pre-transplant recipient peripheral blood mononuclear cell samples from randomized Blood and Marrow Transplant Clinical Trials Network (BMT CTN) studies 0201 (94 patients with bone marrow and 93 with peripheral blood grafts) and 0901 (86 patients with myeloablative and 77 with reduced-intensity conditioning; all using peripheral blood grafts). In multivariable analysis (with a SNP 9 graft source interaction term in CTN-0201 and a SNP 9 conditioning intensity term in CTN-0901), DEFA5 rs4415345 and rs4610776 were associated with altered incidence of aGVHD grade II-IV [rs4415345 G vs. C: hazard ratio (HR) 0Á58, 95% confidence interval (95% CI) 0Á37-0Á92, P = 0Á02; rs4610776 T vs. A: HR 1Á53, 95% CI 1Á01-2Á32, P = 0Á05] in CTN-0201, but not CTN-0901, suggesting a stronger effect in bone marrow allografts. REG3A SNP was not associated with aGVHD. Host genetics may influence aGVHD risk by modulating Paneth cell function.
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The gut mucosal immune system interacts with the gut microbiota; this interaction regulates mucosal and systemic immune responses (Blander et al, 2017) . Gut dysbiosis has been recognized as a risk factor for acute graft-versus-host disease (aGVHD) following allogeneic haematopoietic cell transplantation (allo-HCT) (Jenq et al, 2012; Mathewson et al, 2016; Riwes & Reddy, 2017; Staffas et al, 2017) . The pathogenesis of dysbiosis preceding aGVHD involves disruption of the physiological microbiota-intestinal crosstalk, partly due to the toxicity of transplant conditioning to the gut barrier, prophylactic/therapeutic antibiotics, and possibly dietary changes in the early phase of HCT (Weber et al, 2017a; Whangbo et al, 2017) .
Paneth cells reside at the base of the small intestinal crypts and function as a key component of the gut mucosal innate immune system. They secrete a diverse array of antimicrobial peptides (AMPs) and regulate gut microbial homeostasis (Salzman et al, 2009; Kaech et al, 2010) . a-defensin-5 (HD5), accounting for 70% of the bactericidal peptide activity of Paneth cells (Ayabe et al, 2000; Eriguchi et al, 2013) , has broad antimicrobial properties and shapes the composition of the microbiota (Vaishnava et al, 2008; Salzman et al, 2009) . Accordingly, faecal levels of a-defensins in mice are a surrogate marker for gut microbial homeostasis (Eriguchi et al, 2015) . In return, gut microbiota regulate HD5 expression via the toll-like receptor/myeloid differentiation primary response 88 (TLR/MYD88) and other signalling pathways (Ayabe et al, 2000; Menendez et al, 2013; Sugi et al, 2017) . Regenerating islet-derived protein 3 alpha (Reg3A) is a Ctype lectin that is constitutively expressed and apically secreted by Paneth cells at high levels, with powerful bactericidal activity against gram-positive bacteria of the gut (Cash et al, 2006; Mukherjee et al, 2014) . Reg3A expression in Paneth cells is induced by bacteria via the TLR/MYD88 pathway (Cash et al, 2006; Brandl et al, 2007; Vaishnava et al, 2008) , and by interleukin-22 secreted by type 3 innate lymphoid cells (Zheng et al, 2008) . By limiting the number of mucosal adherent bacteria, Reg3A separates gut microbiota and epithelium, promoting intestinal tolerance to microbial antigens and reducing bacterial translocation (Vaishnava et al, 2011) .
Paneth cell function in mice is partly genetically regulated (Gulati et al, 2012) ; this knowledge is lacking in humans. We hypothesized that potentially functional, recipient single nucleotide polymorphism (SNPs) in the genes for HD5 (DEFA5) or Reg3A (REG3A) may alter the risk of aGVHD. We tested our hypothesis using samples from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocols 0201 and 0901, large randomized trials that compared unrelated donor allo-HCT using peripheral blood versus bone marrow (CTN-0201) (Anasetti et al, 2012) , and related or unrelated donor allo-HCT using myeloablative versus reduced-intensity conditioning (CTN-0901) (Scott et al, 2017) . We demonstrate an association between two recipient SNPs in DEFA5 and aGVHD grade II-IV.
Methods
Clinical data and pre-HCT recipient peripheral blood mononuclear cell samples were provided by the BMT CTN. CTN-0201 was a phase 3 randomized multicentre clinical trial (2004) (2005) (2006) (2007) (2008) (2009) 551 patients) comparing bone marrow (BM) versus peripheral blood (PB) as graft source in allo-HCT from unrelated donors, and with 2-year overall survival as the primary endpoint (Anasetti et al, 2012) . Median follow up for survivors was 2 years. The results demonstrated similar rates of aGVHD between the groups, but higher rates of chronic GVHD among recipients of PB grafts. For BMT CTN-0201, we excluded patients with 1 or more human leucocyte antigen (HLA) locus mismatch (HLA-A, B, C, or DRB1; n = 142), active disease at the time of HCT (n = 24), no remaining research aliquots (n = 176), or only 1 remaining research aliquot (n = 22, reserved for future studies). Exclusion of cases with HLA mismatch was performed because the effect size of SNPs in transplant outcomes is generally small (Karaesmen et al, 2017) and we wanted to eliminate major determinants of aGVHD risk [i.e., HLA mismatch (Verneris et al, 2015) ] to permit visibility of SNP effects. Exclusion of patients with active disease at the time of HCT was due to their expected high relapse risk, which often translates into clinical interventions (both prophylactic and therapeutic) associated with altered risk of aGVHD.
BMT CTN-0901 was a phase 3 randomized multicentre clinical trial (2011) (2012) (2013) (2014) 272 patients, matched sibling or unrelated donors) comparing myeloablative (MA) versus reduced-intensity (RI) conditioning in patients with acute myeloid leukaemia or myelodysplastic syndromes, and with the primary endpoint of 18-month overall survival (Scott et al, 2017) . The graft source was PB in 92% of patients and BM in 8%. Median follow-up for survivors was 2 years. The results demonstrated higher rates of acute and chronic GVHD among MA patients. For BMT CTN-0901, we excluded patients with no available research specimens (n = 21), those who did not undergo a transplant (n = 7), and those who received anti-thymocyte globulin (n = 40), or 1 HLA locus mismatch (HLA-A, B, C, or DRB1; n = 19) grafts. To increase the homogeneity of our study population, we also excluded the minority of patients who received bone marrow allografts (n = 22). All exclusions for 0201 and 0901 samples were pre-specified and performed prior to analysis.
The following intronic upstream variant (2 kb) SNPs with a global minor allele frequency (MAF) of >0Á20 were sequenced: DEFA5 rs4415345G/C (minor allele frequency: 0Á27), DEFA5 rs4610776A/T (MAF: 0Á22), DEFA5 rs6988319G/C (MAF: 0Á26), and REG3A rs7588571A/G (MAF: 0Á49). The only available information about the potential function of these SNPs is an association between rs7588571 non-GG genotype and significantly lower mRNA expression as well as marginally significantly lower protein expression than the GG genotype in one study (Koyama et al, 2017) . SNP sequencing was performed at the University of Minnesota Genomics Center by multiplexed polymerase chain reaction (PCR) of genomic DNA [iPLEX Gold (Sequenom, San Diego, CA, USA) method]. Multiplexed PCR was performed in 5-ll reactions on a 384-well plate containing 10 ng of genomic DNA. Reactions contained 0Á5 U HotStar Taq polymerase (QIAGEN, Valencia, CA, USA), 100 nmol/l primers, 1Á259 HotStar Taq buffer, 1Á625 mmol/l MgCl 2 , and 500 lmol/l dNTPs. Following enzyme activation at 94°C for 15 min, DNA was amplified with 45 cycles of 94°C 9 20 s, 56°C 9 30 s, 72°C 9 1 min, followed by a 3-min extension at 72°C. Unincorporated dNTPs were removed using shrimp alkaline phosphatase (0Á3 units) (Agena, San Diego). Single-base extension was carried out by addition of single base primer extension (SBE) primers at concentrations from 0Á625 lmol/l (low MW primers) to 1Á25 lmol/l (high MW primers) using iPLEX enzyme and buffers (Agena Bioscience, San Diego, CA) in 9-ll reactions. Reactions were desalted and single base extension products measured using the MassARRAY system, and mass spectra analysed using TYPER software (Agena Bioscience), to generate genotype calls and allele frequencies.
For each SNP, an additive allelic model was built to estimate the effect of each additional copy of the minor allele on the cumulative incidence of aGVHD grade II-IV by day +180 using death without aGVHD as a competing risk. Fine and Gray multiple regression models using pre-specified variables for SNP (minor versus major allele), conditioning intensity (RI versus MA), graft source (PB versus BM in 0201), SNP 9 graft source (in 0201) and SNP 9 conditioning intensity (in 0901) were built (Fine & Gray, 1999) . The rationale for including interaction terms was to benefit from the randomized nature of the CTN trials in addressing whether potential SNP effects are limited to one of the randomly assigned groups (PB versus BM and/or RI versus MA), although our exclusions and sample size limit the power of these interaction assessments. We performed our analysis without correction for multiple comparisons, acknowledging the need for future validation studies. Analysis was performed using R version 3.4 (R Foundation for Statistical Computing, Vienna, Austria). P values are two-sided and considered significant when <0Á05.
Results
A total of 187 patients (94 BM, 93 PB) from CTN-0201 and 163 patients (86 MA, 77 RI) from CTN-0901 were included. PB versus BM groups in 0201 and MA versus RI groups in 0901 were similar in all baseline characteristics reflecting the randomized design of the trials (Table I ). There were no significant differences between baseline characteristics of the included patients with different genotypes in each trial (results not shown). Genotypes for all four SNPs were in Hardy-Weinberg equilibrium. The call rate in 0201 samples was 100% for rs4415345, 100% for rs4610776, 97% for rs6988319 and 100% for rs7588571. In 0901 samples, these numbers were 99%, 100%, 96% and 100%, respectively. rs6988319 and rs4415345 were highly correlated (89% genotypic correspondence in 0201 and 92% in 0901), probably reflecting linkage disequilibrium. Therefore, of these two SNPs we only report the results for rs4415345. Figure 1 shows unadjusted associations between SNPs and aGVHD grade II-IV. Additive allelic modelling for 0201 samples adjusted for graft source and conditioning intensity, but with no interaction terms, indicated that the minor allele of rs4415345 was associated with reduced incidence of aGVHD grade II-IV [hazard ratio (HR) 0Á74, 95% confidence interval (95% CI) 0Á54-1Á00, P = 0Á05]. The minor allele of rs4610776 was marginally associated with more aGVHD grade II-IV (HR 1Á31, 95% CI 0Á97-1Á77, P = 0Á08). Next, we investigated whether these associations were stronger in certain subgroups of patients. CTN-0201 provided the ideal opportunity to answer this question for graft source because, with randomization between PB and BM, any graft sourcespecific association between a SNP and aGVHD would be expected to be immune to potential confounding. Multivariable modelling for BMT CTN-0201 samples using a SNP 9 graft source interaction term increased the estimated SNP effect size and demonstrated that the observed aGVHD associations for rs4415345 and rs4610776 were stronger in the BM group (Table II) . In multivariable models including SNP 9 graft source interaction and with BM coded zero, the estimated effect size for a SNP indicates the result in the BM group. This is because the interaction term becomes zero when graft source is BM. Therefore, in the BM group of CTN-0201, each additional minor allele of rs4415345 decreased the risk of aGVHD grade II-IV by approximately 40% (HR 0Á58, 95% CI 0Á37-0Á92; P = 0Á02) and each additional minor allele of rs4610776 increased the risk of aGVHD grade II-IV by approximately 50% (HR 1Á53, 95% CI 1Á01-2Á32; P = 0Á05). Consistent with this finding, we found no significant association between these two SNPs and aGVHD grade II-IV in CTN-0901, which included only PB allografts (P = 0Á61 and 0Á32, respectively). Multivariable modelling for CTN-0901 samples with adjustment for interaction between conditioning intensity and these SNPs was non-significant (Table II) . No significant association was found between rs7588571 and aGVHD grade II-IV in BMT CTN-0201 (HR 0Á92, 95% CI 0Á70-1Á20, P = 0Á54) or CTN-0901 (HR 1Á09, 95% CI 0Á75-1Á58, P = 0Á64).
Finally, because a large number of patients (n = 198) in CTN-0201 were excluded due to unavailability of adequate research samples, we tested whether the excluded patients had a different rate of aGVHD compared with the included patients. This analysis did not show any differences between the groups [HR for included versus excluded patients 1Á1 (95% CI 0Á8-1Á4), P = 0Á7 for aGVHD grade II-IV and 1Á1 (95% CI 0Á7-1Á8), P = 0Á7 for aGVHD grade III-IV]. These results show that a selection bias due to sample availability is unlikely to have occurred.
Discussion
HD5 and Reg3A have high constitutive expression levels in Paneth cells at the base of ileal crypts, supporting their role in baseline regulation of microbial homeostasis, attenuation of mucosal inflammation, and promotion of epithelial differentiation and growth (George et al, 2008; Weber et al, 2017b) . After secretion into the small intestinal lumen, adefensins persist as functional forms throughout the colon (Mastroianni & Ouellette, 2009) characterized by a reduction in commensal bacteria and overall diversity (Eriguchi et al, 2012) . Consistent with this finding, faecal levels of a-defensins are reduced in mice with GVHD (Eriguchi et al, 2015) , patients with gastrointestinal aGVHD have lower expression of HD5 in the small intestine (Weber et al, 2017b) , and recombinant a-defensin protects against dysbiosis and GVHD in mice (Hayase et al, 2017) .
The bactericidal activity of a-defensins is predominantly limited to non-commensal bacteria (Masuda et al, 2011) , the expansion (secondary to loss of commensals) of which has been associated with aGVHD (Holler et al, 2014; Shono et al, 2016; Weber et al, 2017a) . Lower Paneth cell numbers at onset of gastrointestinal aGVHD predict higher clinical severity and mortality (Levine et al, 2013) , the effect of which might be exaggerated in patients with SNPs associated with reduced AMP secretion. Similarly, patients with gastrointestinal GVHD have a lower expression of Reg3A in the small intestine and higher serum Reg3A levels (Weber et al, 2017b) . Plasma levels of Reg3A at the onset of intestinal GVHD predict response to therapy and non-relapse mortality (Ferrara et al, 2011; Harris et al, 2012) . Finally, transgenic expression of human REG3A in mice altered the faecal microbiota and protected against dextran sodium sulfateinduced colitis (Darnaud et al, 2018) . Host genetics influence gut microbiota (Goodrich et al, 2014 (Goodrich et al, , 2016 (Goodrich et al, , 2017 . Approximately one-third of faecal bacterial taxa are heritable (Turpin et al, 2016) , e.g., Bifidobacterium in association with host lactase gene (LCT) locus and Blautia in association with CD36 gene locus (Goodrich et al, 2016) . In patients with inflammatory bowel disease, host NOD2 SNPs are associated with Enterobacteriaceae abundance (Knights et al, 2014) . Lower levels of gut microbiota diversity have been associated with increased risk of aGVHD (Holler et al, 2014; Jenq et al, 2015) , suggesting that microbiota-relevant host SNPs may have implications for aGVHD. Consistent with this hypothesis, a previous study showed that a recipient SNP of FUT2, the gene for fucosyltransferase 2 (an enzyme that regulates the gut microbiome by synthesizing the H antigen on the intestinal mucosa), modifies the risk of aGVHD (Rayes et al, 2016) .
Using samples from two large randomized trials, we found evidence for the role of Paneth cell DEFA5 SNPs in modulating the risk of aGVHD grade II-IV. This association was stronger in bone marrow graft recipients. We speculate that the different cellular composition of graft products obtained from BM versus PB influences the relative contribution of SNPs to alloreactive tissue damage. These SNPs may alter the mucosal levels of HD5, resulting in gut dysbiosis and aGVHD. Our results support the increasingly recognized role of intestinal dysbiosis in the pathogenesis of aGVHD. Given our limited progress in the treatment of aGVHD, predictive methods that allow for early intervention are desirable (Rashidi et al, 2016) . Of interest are recipient or donor genetic characteristics because they can be identified before allo-HCT. However, considering the limited sample size of specific subgroups in this study, our results suggesting graft source-specific associations should be interpreted with caution and further research to validate the results in a BM only group is warranted. We were also limited by lack of information about the functional effects of DEFA5 SNPs. Future work needs to explore any functional impact of SNPs, especially on intestinal tissue expression of DEFA5 and peritransplant microbiota ecology. If our results are corroborated in independent validation cohorts, DEFA5 SNPs may be incorporated into composite aGVHD risk stratification models to permit individualized, risk-based GVHD prophylaxis.
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